WFS1 and type 1 diabetes mellitus: This is particularly relevant given that longitudinal studies have indicated significant variability in treatment response to mono-agonists: for instance, approximately 50% of Wfs1 KO rats developed insulin-dependent diabetes despite lifelong Liraglutide treatment that commenced in the pre-symptomatic phase (16).